MyoKardia Inc (MYOK):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MyoKardia Inc (MYOK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9981
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. The company utilizes precision medicine platform to develop therapies for rare cardiovascular diseases including heritable cardiomyopathies. The company’s pipeline products include therapeutic programs for the treatment of heritable cardiomyopathy including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Its lead product candidate, mavacamten, is intended for the treatment of symptomatic oHCM. Its other pipeline product MYK-491 is an orally-administered small molecule to treat genetic DCM caused by mutations in sarcomeric proteins. The company is collaborated with many healthcare organizations for the development and commercialization of product candidates. MyoKardia is headquartered in South San Francisco, California, the US.

MyoKardia Inc (MYOK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MyoKardia Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MyoKardia Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
MyoKardia Raises USD46 Million in Series B Financing 11
MyoKardia Raises USD10 Million in Venture Financing 12
MyoKardia Raises US$38 Million In Series A Financing 13
Partnerships 14
MyoKardia Enters into Partnership with 23andMe 14
Sanofi Extends its Co-Development Agreement with MyoKardia 15
Equity Offering 16
MyoKardia Raises USD183.7 Million in Public Offering of Shares 16
MyoKardia Raises USD143 Million in Public Offering of Shares 18
Myokardia Plans to Raise up to USD122.2 Million in Public Offering of Shares 20
MyoKardia Raises USD65.6 Million in Public Offering Shares 21
MyoKardia Raises USD62.5 Million in IPO 23
MyoKardia Raises USD5 Million in Private Placement of Series B Redeemable Convertible Preferred Stock 25
MyoKardia Raises USD40 Million in Private Placement of Series B Redeemable Convertible Preferred Stock for USD40.99 Million 26
MyoKardia Raises USD10 Million in Private Placement of Series A-1 Redeemable Convertible Preferred Stock 27
MyoKardia Raises USD6 Million in Private Placement of Preferred Stock 28
MyoKardia Raises USD5 Million in Private Placement of Shares 29
MyoKardia Raises USD8 Million in Private Placement of Preferred Stock 30
MyoKardia Raises USD5.3 Million in Private Placement of Preferred Stock 31
MyoKardia Raises USD5.4 Million in Private Placement of Preferred Stock 32
MyoKardia Raises USD0.04 Million in Private Placement of Shares 33
MyoKardia Raises USD4.6 Million in Private Placement of Preferred Stock 34
MyoKardia Raises USD4 Million in Private Placement of Preferred Stock 35
MyoKardia Inc – Key Competitors 36
MyoKardia Inc – Key Employees 37
MyoKardia Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 08, 2018: MyoKardia reports second quarter 2018 financial results 39
May 08, 2018: MyoKardia Reports First Quarter 2018 Financial Results 41
Mar 08, 2018: MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 02, 2017: MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress 45
Aug 07, 2017: MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress 46
Mar 13, 2017: MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress 48
Corporate Communications 50
Apr 04, 2018: MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer 50
Apr 18, 2017: MyoKardia Appoints David Meeker, M.D., to Board of Directors 51
Mar 17, 2017: MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors 52
Feb 01, 2017: MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs 53
Government and Public Interest 54
Aug 23, 2018: New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation 54
Clinical Trials 56
Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day 56
Oct 30, 2018: MyoKardia shares data on new research program MYK-224 at its 2018 R&D in Day New York City 57
Aug 07, 2017: MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy 58
Other Significant Developments 60
Sep 20, 2018: MyoKardia launches inaugural MyoSeeds research grants program to advance independent research in heart disease 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
MyoKardia Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MyoKardia Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MyoKardia Inc, Deals By Therapy Area, 2012 to YTD 2018 9
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
MyoKardia Raises USD46 Million in Series B Financing 11
MyoKardia Raises USD10 Million in Venture Financing 12
MyoKardia Raises US$38 Million In Series A Financing 13
MyoKardia Enters into Partnership with 23andMe 14
Sanofi Extends its Co-Development Agreement with MyoKardia 15
MyoKardia Raises USD183.7 Million in Public Offering of Shares 16
MyoKardia Raises USD143 Million in Public Offering of Shares 18
Myokardia Plans to Raise up to USD122.2 Million in Public Offering of Shares 20
MyoKardia Raises USD65.6 Million in Public Offering Shares 21
MyoKardia Raises USD62.5 Million in IPO 23
MyoKardia Raises USD5 Million in Private Placement of Series B Redeemable Convertible Preferred Stock 25
MyoKardia Raises USD40 Million in Private Placement of Series B Redeemable Convertible Preferred Stock for USD40.99 Million 26
MyoKardia Raises USD10 Million in Private Placement of Series A-1 Redeemable Convertible Preferred Stock 27
MyoKardia Raises USD6 Million in Private Placement of Preferred Stock 28
MyoKardia Raises USD5 Million in Private Placement of Shares 29
MyoKardia Raises USD8 Million in Private Placement of Preferred Stock 30
MyoKardia Raises USD5.3 Million in Private Placement of Preferred Stock 31
MyoKardia Raises USD5.4 Million in Private Placement of Preferred Stock 32
MyoKardia Raises USD0.04 Million in Private Placement of Shares 33
MyoKardia Raises USD4.6 Million in Private Placement of Preferred Stock 34
MyoKardia Raises USD4 Million in Private Placement of Preferred Stock 35
MyoKardia Inc, Key Competitors 36
MyoKardia Inc, Key Employees 37
MyoKardia Inc, Subsidiaries 38

List of Figures
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[MyoKardia Inc (MYOK):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Novozymes AS (NZYM B):企業の財務・戦略的SWOT分析
    Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bank Of Ningbo Co. Ltd.:企業の戦略・SWOT・財務分析
    Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank Of Ningbo Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Kuwait Company for Process Plant Construction & Contracting K.S.C.:企業の戦略・SWOT・財務情報
    The Kuwait Company for Process Plant Construction & Contracting K.S.C. - Strategy, SWOT and Corporate Finance Report Summary The Kuwait Company for Process Plant Construction & Contracting K.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information …
  • Boart Longyear Ltd:企業の戦略・SWOT・財務分析
    Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report Summary Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析
    Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Jardine Cycle & Carriage Ltd (C07):企業の財務・戦略的SWOT分析
    Jardine Cycle & Carriage Ltd (C07) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Abercrombie & Fitch Co:企業の戦略・SWOT・財務分析
    Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report Summary Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • The Broad Institute Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation is a non-profit research organization that conducts genomic research for treatment of human diseases. The organization transforms medicine by utilizing systematic approaches in biological sciences, to speed up th …
  • BARMER GEK:企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Elk Petroleum Ltd (ELK):石油・ガス:M&Aディール及び事業提携情報
    Summary Elk Petroleum Ltd (Elk) is an oil and gas company that explore, produce, and develops oil and gas properties. The company operates projects in Grieve oil field and Singleton oil field. Its Grieve oil field development project is a joint venture between the company and Denbury Resources, a pe …
  • The Medicines Company (MDCO):医療機器:M&Aディール及び事業提携情報
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle …
  • Venture Minerals Ltd (VMS):企業の財務・戦略的SWOT分析
    Summary Venture Minerals Ltd (Venture Minerals) is a mining and mineral exploration and development company that develops, discovers and explores mineral deposits. The company explores for gold, tin, magnetite, copper and tungsten deposits, among others. It provides projects such as Paulsens South p …
  • Viridian Group Investments Ltd:企業の戦略的SWOT分析
    Viridian Group Investments Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Ultrastroy Eood:企業の戦略的SWOT分析
    Ultrastroy Eood - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Corporation Bank:企業のM&A・事業提携・投資動向
    Corporation Bank - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Corporation Bank Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • NuVasive Inc (NUVA):企業の製品パイプライン分析2018
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • The McClatchy Company:企業の戦略・SWOT・財務分析
    The McClatchy Company - Strategy, SWOT and Corporate Finance Report Summary The McClatchy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sika Interplant Systems Limited:企業の戦略・SWOT・財務分析
    Sika Interplant Systems Limited - Strategy, SWOT and Corporate Finance Report Summary Sika Interplant Systems Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mitsui Oil Exploration Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Mitsui Oil Exploration Co., Ltd. (MOECO), a subsidiary of Mitsui & Co., Ltd, is an upstream oil and gas company. The company explores for, develops and produces oil, natural gas and condensate from its assets. It is also involved in a geothermal energy project. The company also holds investm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆